In summary, we show that in human breast cancer cell lines increased levels of HER2 expression alone are associated with increased effectiveness of anti-EGFR therapy, alone or in combination with anti-HER2 therapy, and that the combination of EGFR and HER3 overexpression may be an even better predictor of response. The gene discussed is ERBB2; the disease is breast carcinoma.